PVI
JNCE

Pura Vida Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Pura Vida Investments’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21,700
Closed -$485K – 116
2018
Q1 		$485K Buy
+21,700
New +$482K 0.29% 61

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Pura Vida Investments's JNCE Position: Q2 2018 in Review

Pura Vida Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2018, closing a stake of 21,700 shares — an estimated $485K sold.

Pura Vida Investments first reported a position in JNCE in Q1 2018 and held it in 1 quarter. The position peaked at $485K in Q1 2018. 83 funds tracked by Wall St. Rank hold JNCE as of Q2 2018.

  • Pura Vida Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Pura Vida Investments sold 21,700 Jounce Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $485K.
  • Pura Vida Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Pura Vida Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $485K in Q1 2018.
  • 83 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2018.

Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.